U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07746141) titled 'A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations' on July 30.
Brief Summary: The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
Study Start Date: Sept. 04
Study Type: INTERVENTIONAL
Condition:
RAS Mutation
Advanced Solid Tumor
Metastatic Solid Tumor
Intervention:
DRUG: BG-85738
Administered orally
DRUG: Tislelizumab
Administered intravenously
DRUG: Cetuxim...